Israel Active

Israel’s Teva and Sanofi announced promising Phase 2 trial results for duvakitug, designed to treat colitis and Crohn’s disease. In a 14-week phase 2b multi-national study, nearly 50% of patients achieved clinical remission compared with around 20% on a placebo. Teva’s shares rose 15%.

Surgeons at Jerusalem’s Hadassah Ein Kerem removed a dangerous tumor from the spine of a Jerusalem teenager. They used Israel’s PathKeeper Visionary Surgical Nav System (see previously) to maintain precision and avoid damaging the teen’s spinal nerves.

The American Friends of Magen David Adom (AFMDA) Gala raised a total of $4 million to support Israel’s leading emergency service. It also honored actress and pro-Israel advocate Patricia Heaton, with the Champion of Israel Award.

Israel’s largest hospital, Sheba Medical Center, has opened a branch of its ARC (Sheba’s health transformation and innovation arm) at the Institut de Cancérologie de l’Ouest (ICO) in Nantes, France.  It will help ICO’s 1,400 professionals, who treat over 48,000 patients annually.

Researchers at the Hebrew University of Jerusalem have created a new model for assessing patients on admission to hospital. They enhanced the standard Elixhauser Comorbidity model to include test results, vital signs, and demographic data, with up to 18% better predictions of outcomes.

Israel’s FIZE Medical (see previously) has monitored over 4,000 patients at high risk of Acute Kidney Injury (AKI) since its launch last year at leading hospitals in the U.S. and Israel. In 2025 it plans to expand operations in Japan and Europe and enhance its production infrastructure in Israel and Vietnam.

At Hadassah Ein Kerem, Moriel Indek gave birth to a healthy baby boy after undergoing brain surgery during her pregnancy with her third child. A non-malignant tumor close to her optic nerve was growing, requiring surgeons to urgently operate.

Nazia Matar (63) had life-threatening heart arrhythmia with no possible surgical solution. Cardiologist Prof. Mahmoud Suleiman at Haifa’s Rambam hospital detected the root cause and directed a single, high-dose of radiation at the problem tissue. Nazia is now completely cured.

Israel’s Promise Bio is researching immune-mediated disease treatment with advanced precision medicine solutions. Using mass-spectrometry data and AI analysis (called epiproteomics), it aims to identify the best medications to treat a particular patient’s autoimmune disease.

A first-in-the-world clinical trial taking place at the Hadassah Medical Organization in Jerusalem will directly test whether the Bacillus Calmette-Guérin (BCG) TB vaccine (see previously) should be widely administered in the fight against Alzheimer’s.